Jared Heiner, MD
Urology · Meridian, IDNPI 1710097068
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,410 of the $3,075 with a category attached, or 78.4%. 23 manufacturers reported payments, led by Neotract Inc. at 27.3% of the total. Reporting peaked in 2020 at $972 and has fallen 55.6% since, to $432 in 2025. That places this record below the midpoint for urology clinicians in ID, where the typical reported total is $3,075.
Across 101 payments — averaging $30.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neotract Inc.$838
- Boston Scientific$601
- AbbVie$288
- Teleflex LLC$239
- Procept Biorobotics Corporation$211
- Astellas Pharma US Inc$148
- plus $750 from 17 others
What the payments were for
- Travel & lodging$59819%
- Food & beverage$2,41078%
- Education$662%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neotract Inc. | 13 | $838 |
| Boston Scientific | 22 | $601 |
| AbbVie(2 entities) | 11 | $288 |
| Teleflex LLC | 7 | $239 |
| Procept Biorobotics Corporation | 3 | $211 |
| Astellas Pharma US Inc | 6 | $148 |
| Johnson & Johnson | 6 | $123 |
| 180 Medical, Inc. | 4 | $75 |
| Myovant Sciences Inc. | 4 | $67 |
| Sumitomo Pharma America, Inc. | 2 | $61 |
| Coloplast | 4 | $56 |
| Endo Pharmaceuticals Inc. | 3 | $51 |
| Convatec Inc. | 2 | $47 |
| Merck | 1 | $44 |
| Bayer | 2 | $42 |
| Intuitive Surgical | 1 | $41 |
| Urogen Pharma, Inc. | 1 | $34 |
| Telix Pharmaceuticals | 1 | $29 |
| Myriad Genetic Laboratories, Inc. | 2 | $27 |
| Dendreon Pharmaceuticals LLC | 1 | $16 |
| Pfizer | 1 | $14 |
| Tolmar Pharmaceuticals, Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 3 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$583
- AquaBeam Robotic System$145
- BOTOX$111
How this compares
$3,075 in reported general payments places this provider in the 50th percentile of 55 urology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 29 | $17,038 |
| MyrbetriqMirabegron | 13 | $14,446 |
| Testosterone | 12 | $3,620 |
| Tamsulosin Hcl | 264 | $3,507 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 138 | $2,603 |
| Testosterone Cypionate | 40 | $2,439 |
| Potassium Citrate ErPotassium Citrate | 12 | $1,770 |
| Dutasteride | 54 | $1,092 |
| Solifenacin Succinate | 20 | $957 |
| Terazosin Hcl | 28 | $742 |
| Finasteride | 64 | $719 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 56 | $198 |
| Oxybutynin Chloride | 53 | $182 |
| Ciprofloxacin Hcl | 30 | $116 |
| Tramadol Hcl | 49 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $61 | $17,03829 claims |
| Astellas Pharma US IncMyrbetriq | $148 | $14,44613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 55 urology providers in Idaho.
Other urology in Meridian
- Wade MunceyMeridian$9K
- John GreerMeridian$8K
- Dawn KingMeridian$8K
- Helen KuoMeridian$5K
- Brian AugeMeridian$5K
- Michael JacobsonMeridian$4K
- Kara SaperstonMeridian$4K
- Joseph WilliamsMeridian$4K
- Lisa ParrilloMeridian$3K
- Michael TaylorMeridian$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.